Literature DB >> 23178301

Effects of the activin A-myostatin-follistatin system on aging bone and muscle progenitor cells.

Matthew Bowser1, Samuel Herberg, Phonepasong Arounleut, Xingming Shi, Sadanand Fulzele, William D Hill, Carlos M Isales, Mark W Hamrick.   

Abstract

The activin A-myostatin-follistatin system is thought to play an important role in the regulation of muscle and bone mass throughout growth, development, and aging; however, the effects of these ligands on progenitor cell proliferation and differentiation in muscle and bone are not well understood. In addition, age-associated changes in the relative expression of these factors in musculoskeletal tissues have not been described. We therefore examined changes in protein levels of activin A, follistatin, and myostatin (GDF-8) in both muscle and bone with age in C57BL6 mice using ELISA. We then investigated the effects of activin A, myostatin and follistatin on the proliferation and differentiation of primary myoblasts and mouse bone marrow stromal cells (BMSCs) in vitro. Myostatin levels and the myostatin:follistatin ratio increased with age in the primarily slow-twitch mouse soleus muscle, whereas the pattern was reversed with age in the fast-twitch extensor digitorum longus muscle. Myostatin levels and the myostatin:follistatin ratio increased significantly (+75%) in mouse bone marrow with age, as did activin A levels (+17%). Follistatin increased the proliferation of primary myoblasts from both young and aged mice, whereas myostatin increased proliferation of younger myoblasts but decreased proliferation of older myoblasts. Myostatin reduced proliferation of both young and aged BMSCs in a dose-dependent fashion, and activin A increased mineralization in both young and aged BMSCs. Together these data suggest that aging in mice is accompanied by changes in the expression of activin A and myostatin, as well as changes in the response of bone and muscle progenitor cells to these factors. Myostatin appears to play a particularly important role in the impaired proliferative capacity of muscle and bone progenitor cells from aged mice.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23178301      PMCID: PMC3678732          DOI: 10.1016/j.exger.2012.11.004

Source DB:  PubMed          Journal:  Exp Gerontol        ISSN: 0531-5565            Impact factor:   4.032


  40 in total

1.  Prolonged absence of myostatin reduces sarcopenia.

Authors:  Victoria Siriett; Leanne Platt; Mônica Senna Salerno; Nicholas Ling; Ravi Kambadur; Mridula Sharma
Journal:  J Cell Physiol       Date:  2006-12       Impact factor: 6.384

2.  Age-related loss of muscle mass and bone strength in mice is associated with a decline in physical activity and serum leptin.

Authors:  Mark W Hamrick; Ke-Hong Ding; Catherine Pennington; Yuh J Chao; Yii-Der Wu; Boyd Howard; David Immel; Cesario Borlongan; Paul L McNeil; Wendy B Bollag; Walton W Curl; Jack Yu; Carlos M Isales
Journal:  Bone       Date:  2006-06-05       Impact factor: 4.398

3.  Antibody-directed myostatin inhibition in 21-mo-old mice reveals novel roles for myostatin signaling in skeletal muscle structure and function.

Authors:  Kate T Murphy; René Koopman; Timur Naim; Bertrand Léger; Jennifer Trieu; Chikwendu Ibebunjo; Gordon S Lynch
Journal:  FASEB J       Date:  2010-07-12       Impact factor: 5.191

4.  Serum myostatin-immunoreactive protein is increased in 60-92 year old women and men with muscle wasting.

Authors:  K E Yarasheski; S Bhasin; I Sinha-Hikim; J Pak-Loduca; N F Gonzalez-Cadavid
Journal:  J Nutr Health Aging       Date:  2002       Impact factor: 4.075

5.  Loss of myostatin (GDF8) function increases osteogenic differentiation of bone marrow-derived mesenchymal stem cells but the osteogenic effect is ablated with unloading.

Authors:  M W Hamrick; X Shi; W Zhang; C Pennington; H Thakore; M Haque; B Kang; C M Isales; S Fulzele; K H Wenger
Journal:  Bone       Date:  2007-02-23       Impact factor: 4.398

6.  Endocrine actions of myostatin: systemic regulation of the IGF and IGF binding protein axis.

Authors:  Nolann G Williams; Jillian P Interlichia; Melissa F Jackson; David Hwang; Pinchas Cohen; Buel D Rodgers
Journal:  Endocrinology       Date:  2010-12-08       Impact factor: 4.736

Review 7.  Myostatin (GDF-8) as a key factor linking muscle mass and bone structure.

Authors:  M N Elkasrawy; M W Hamrick
Journal:  J Musculoskelet Neuronal Interact       Date:  2010-03       Impact factor: 2.041

8.  Comparison of GH, IGF-I, and testosterone with mRNA of receptors and myostatin in skeletal muscle in older men.

Authors:  T J Marcell; S M Harman; R J Urban; D D Metz; B D Rodgers; M R Blackman
Journal:  Am J Physiol Endocrinol Metab       Date:  2001-12       Impact factor: 4.310

9.  Skeletal muscle-derived progenitors capable of differentiating into cardiomyocytes proliferate through myostatin-independent TGF-beta family signaling.

Authors:  Tetsuya Nomura; Tomomi Ueyama; Eishi Ashihara; Kento Tateishi; Satoshi Asada; Norio Nakajima; Koji Isodono; Tomosaburo Takahashi; Hiroaki Matsubara; Hidemasa Oh
Journal:  Biochem Biophys Res Commun       Date:  2007-11-29       Impact factor: 3.575

10.  Skeletal muscle atrophy in old rats: differential changes in the three fiber types.

Authors:  J O Holloszy; M Chen; G D Cartee; J C Young
Journal:  Mech Ageing Dev       Date:  1991-10       Impact factor: 5.432

View more
  28 in total

1.  A myostatin inhibitor (propeptide-Fc) increases muscle mass and muscle fiber size in aged mice but does not increase bone density or bone strength.

Authors:  Phonepasong Arounleut; Peter Bialek; Li-Fang Liang; Sunil Upadhyay; Sadanand Fulzele; Maribeth Johnson; Mohammed Elsalanty; Carlos M Isales; Mark W Hamrick
Journal:  Exp Gerontol       Date:  2013-07-04       Impact factor: 4.032

Review 2.  Aging and the muscle-bone relationship.

Authors:  Susan A Novotny; Gordon L Warren; Mark W Hamrick
Journal:  Physiology (Bethesda)       Date:  2015-01

Review 3.  Bone Pain and Muscle Weakness in Cancer Patients.

Authors:  Daniel P Milgrom; Neha L Lad; Leonidas G Koniaris; Teresa A Zimmers
Journal:  Curr Osteoporos Rep       Date:  2017-04       Impact factor: 5.096

Review 4.  Therapies for musculoskeletal disease: can we treat two birds with one stone?

Authors:  Christian M Girgis; Nancy Mokbel; Douglas J Digirolamo
Journal:  Curr Osteoporos Rep       Date:  2014-06       Impact factor: 5.096

5.  Myoblasts from intrauterine growth-restricted sheep fetuses exhibit intrinsic deficiencies in proliferation that contribute to smaller semitendinosus myofibres.

Authors:  Dustin T Yates; Derek S Clarke; Antoni R Macko; Miranda J Anderson; Leslie A Shelton; Marie Nearing; Ronald E Allen; Robert P Rhoads; Sean W Limesand
Journal:  J Physiol       Date:  2014-05-23       Impact factor: 5.182

6.  Administration of an activin receptor IIB ligand trap protects male juvenile rhesus macaques from simian immunodeficiency virus-associated bone loss.

Authors:  Wen Guo; Karol M Pencina; Karyn O'Connell; Monty Montano; Liming Peng; Susan Westmoreland; Julie Glowacki; Shalender Bhasin
Journal:  Bone       Date:  2017-01-26       Impact factor: 4.398

7.  MicroRNA-183-5p Increases with Age in Bone-Derived Extracellular Vesicles, Suppresses Bone Marrow Stromal (Stem) Cell Proliferation, and Induces Stem Cell Senescence.

Authors:  Colleen Davis; Amy Dukes; Michelle Drewry; Inas Helwa; Maribeth H Johnson; Carlos M Isales; William D Hill; Yutao Liu; Xingming Shi; Sadanand Fulzele; Mark W Hamrick
Journal:  Tissue Eng Part A       Date:  2017-04-28       Impact factor: 3.845

Review 8.  Current understanding of sarcopenia: possible candidates modulating muscle mass.

Authors:  Kunihiro Sakuma; Wataru Aoi; Akihiko Yamaguchi
Journal:  Pflugers Arch       Date:  2014-05-07       Impact factor: 3.657

Review 9.  Molecular mechanism of sarcopenia and cachexia: recent research advances.

Authors:  Kunihiro Sakuma; Wataru Aoi; Akihiko Yamaguchi
Journal:  Pflugers Arch       Date:  2017-01-19       Impact factor: 3.657

Review 10.  Myostatin--the holy grail for muscle, bone, and fat?

Authors:  B Buehring; N Binkley
Journal:  Curr Osteoporos Rep       Date:  2013-12       Impact factor: 5.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.